Research programme: chimeric antigen receptor T cell therapeutics - Noile-Immune Biotech/Takeda Oncology

Drug Profile

Research programme: chimeric antigen receptor T cell therapeutics - Noile-Immune Biotech/Takeda Oncology

Alternative Names: Allogenic prime CAR-T - Noile-Immune Biotech; Autologous prime CAR-T - Noile-Immune Biotech; NIB-101; NIB-102; NIB-103; NIB-104; NIB-105; NIB-201

Latest Information Update: 08 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Yamaguchi University
  • Developer Noile-Immune Biotech; Takeda Oncology
  • Class CAR-T cell therapies; Gene therapies; Immunotherapies
  • Mechanism of Action T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Solid tumours

Most Recent Events

  • 04 Sep 2017 Noile-Immune Biotech and Takeda agree to research and develop CAR-T cells for Solid tumours
  • 04 Sep 2017 Preclinical trials in Solid tumours in Japan (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top